摘要
ER、PR、HER-2在乳腺癌中是指导治疗和判断预后的重要的生物学标志物。随着乳腺癌的病情进展,ER、PR、HER-2的表达在原发灶及转移灶中可能存在差异。目前临床医师已意识到对转移灶进行受体检测的必要性。该文结合目前的研究现状就上述问题进行综述。
ER, PR, HER-2 are signiifcant biological markers in guiding the choice of treatment and evaluating clinical prognosis. As the progression of tumor cells, the expressions of these receptors in recurrent tumors may be different from primary tumors. Nowadays clinicians have realized the necessity of receptor detection in the metastatic lesions. This article summarized the current research status on the above issues.
出处
《中国癌症杂志》
CAS
CSCD
北大核心
2015年第2期155-160,共6页
China Oncology
关键词
乳腺癌
受体
表达
Breast cancer
Receptor
Expression
